Apsolol
Hepatic Encephalopathy
Floatz Rating
BB64/100
Confidence
Indicative
Sponsor
West China Hospital
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
53Moderate confidence
Detailed axis rationale is planned and will be published soon.
No trial-level evidence is linked to this axis yet.
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Hepatic Encephalopathy
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Apsolol (this asset) | West China Hospital | Approved | BB · 64 |
| L-Ornithine L-Aspartate | Jinnah Postgraduate Medical Centre | P4 | BBB |
| Rifaximin | General Hospital of Shenyang Military Region | P4 | BBB |
| Lactulose | General Hospital of Shenyang Military Region | P4 | BBB |
| Normal Human Serum Albumin | General Hospital of Shenyang Military Region | P4 | BB |
| L-Ornithine-L-Aspartate | Qurratul Ain Jamil | P4 | BB |
| Ornithine | Imperial College London | P4 | BB |
| Lactose | Centro Regional para el Estudio de las Enfermedades Digestivas | P4 | BB |
| Blood, Whole | Imperial College London | P4 | BB |
+38 more in the Hepatic Encephalopathy cohort
Other indications for Apsolol
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Esophageal Varices | — | P4 | BBB · 74 |
| Migraine Disorder | — | P4 | BBB · 74 |
| Esophageal Varices With Bleeding | — | P4 | BBB · 73 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Citation
Floatz Terminal. Apsolol in Hepatic Encephalopathy. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 13, 2026. https://terminal.floatz.ai/assets/apsolol-hepatic-encephalopathy
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →